SMARCB1 (INI-1) deficient sinonasal carcinoma of the right maxillary sinus - A rare entity.

Int J Surg Case Rep

Department of Pathology and Lab Medicine, AIIMS, Bhopal 462020, Madhya Pradesh, India. Electronic address:

Published: September 2024

AI Article Synopsis

  • SMARCB1 (INI-1) is a crucial tumor suppressor gene that prevents tumor formation in the SWI/SNF complex, and its mutations lead to aggressive SMARCB1-deficient tumors, such as sinonasal carcinomas, known for poorer prognosis, especially in elderly patients.
  • A case study of a 66-year-old male with a 4-month-old cheek swelling was diagnosed with a SMARCB1-deficient sinonasal carcinoma, leading to a subtotal maxillectomy and subsequent chemotherapy and radiotherapy, resulting in no signs of recurrence at a 13-month follow-up.
  • The study emphasizes that the loss of INI-1 expression due to homozygous deletion of SMARCB1 is

Article Abstract

Introduction And Importance: SMARCB1 (INI-1) is a vital tumour suppressor gene on chromosome 22q11.2, preventing tumour development in the SWI/SNF complex. Mutations cause SMARCB1-deficient tumours with distinct features. Loss of INI-1 expression is seen in malignancies, including sinonasal carcinoma and atypical teratoid/rhabdoid tumours. Recently recognized as a separate entity, SMARCB1-deficient sinonasal carcinomas (SDSC) are rare, clinically aggressive, and mimic other malignancies, emphasizing their significant diagnosis due to poorer prognosis, particularly in the elderly.

Case Presentation: A 66-year-old male presented with a 4-month-old right cheek swelling, diagnosed initially as a sinonasal neoplastic mass. The biopsy revealed sinonasal mucosal fragments infiltrated by a tumour with plasmacytoid morphology. Immunohistochemistry (IHC) of the tumour cells was positive for p63 and pan-cytokeratin and showed INI-1 loss. Subsequent subtotal maxillectomy was performed, and the patient received adjuvant chemotherapy and radiotherapy. At a thirteen-month follow-up, the patient achieved his daily activities with no signs of recurrence.

Clinical Discussion: The loss of protein expression in sinonasal cancer is predominantly attributed to the homozygous deletion of SMARCB1. SDSC, a profoundly invasive malignant carcinoma, tends to infiltrate sinuses and extend into the intracranial regions. The IHC findings of our case were in coherence with previous studies in SMARCB1. The prognosis is particularly unfavourable in males and advanced tumours.

Conclusion: The tumour's microscopic and immunohistochemical characteristics indicated the SDSC. Due to its aggressive nature and high mortality rates, dealing with a paranasal mass, one should be suspicious of this tumour.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11347056PMC
http://dx.doi.org/10.1016/j.ijscr.2024.110021DOI Listing

Publication Analysis

Top Keywords

smarcb1 ini-1
8
sinonasal carcinoma
8
sinonasal
6
tumour
5
smarcb1
4
ini-1 deficient
4
deficient sinonasal
4
carcinoma maxillary
4
maxillary sinus
4
sinus rare
4

Similar Publications

Article Synopsis
  • A 50-year-old man presented with a large mass in his left thigh causing significant pain and impaired functionality, with imaging showing widespread tumors in several body parts, but the primary cancer source was unknown.
  • Despite rapid tumor progression, he began treatment with nivolumab, an immunotherapy drug, and further genomic profiling led to a re-diagnosis of SMARCA4-deficient epithelioid sarcoma.
  • After 5 weeks of treatment, the patient showed significant improvement despite facing some immune-related side effects; by the 12th dose, he had a positive response to the therapy with no new complications.
View Article and Find Full Text PDF

Extrarenal rhabdoid tumors (ERRTs) are highly aggressive pediatric tumors with very few cases reported in the literature. These tumors, similar to their renal counterparts, are characterized by inactivating mutations of the SMARCB1/INI-1 gene, a member of the SWI/SNF chromatin remodeling pathway. Diagnosis of ERRTs appears challenging owing to its rarity, varied morphological profile with a higher tendency for rhabdoid differentiation, and overlapping features with other SMARCB-1 deficient tumors.

View Article and Find Full Text PDF

Primary adenocarcinoma of the spermatic cord: a case report and review of the literature.

Diagn Pathol

October 2024

Department of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, No. 651, Dongfeng Road East, Guangzhou, 510060, China.

Article Synopsis
  • * Histological and immunohistochemical analyses revealed characteristic features of the adenocarcinoma, including specific staining patterns and a complete loss of INI-1 expression.
  • * The findings highlight the importance of understanding rare tumors like this one and encourage further research into potential therapeutic approaches for tumors deficient in SMARCB1.
View Article and Find Full Text PDF

SMARCB1 (INI-1) deficient sinonasal carcinoma of the right maxillary sinus - A rare entity.

Int J Surg Case Rep

September 2024

Department of Pathology and Lab Medicine, AIIMS, Bhopal 462020, Madhya Pradesh, India. Electronic address:

Article Synopsis
  • SMARCB1 (INI-1) is a crucial tumor suppressor gene that prevents tumor formation in the SWI/SNF complex, and its mutations lead to aggressive SMARCB1-deficient tumors, such as sinonasal carcinomas, known for poorer prognosis, especially in elderly patients.
  • A case study of a 66-year-old male with a 4-month-old cheek swelling was diagnosed with a SMARCB1-deficient sinonasal carcinoma, leading to a subtotal maxillectomy and subsequent chemotherapy and radiotherapy, resulting in no signs of recurrence at a 13-month follow-up.
  • The study emphasizes that the loss of INI-1 expression due to homozygous deletion of SMARCB1 is
View Article and Find Full Text PDF

Background: We evaluate outcomes of SMARCB1-deficient sinonasal carcinomas in the largest single-institution study.

Methods: Retrospective cross-sectional study of patients with SMARCB1-deficient sinonasal carcinoma between 1998 and 2024. Disease-specific survival (DSS) and recurrence-free probability (RFP) at 1 and 5 years were measured by Kaplan-Meier method.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!